Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

NEXT STORY
Companion Diagnostics Market Size Worth USD 8.80 Billion by 2027 at 20.29% CAGR – Report by Market Research Future (MRFR)
PREV STORY
Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Philips spotlights integrated diagnostics in oncology at ASCO 2019

author_avatar
NASDAQ Market News

AB Science tiendra une conférence virtuelle sur les résultats du masitinib dans le cancer du pancréas le vendredi 11 décembre 2020

author_avatar
NASDAQ Market News

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

author_avatar
NASDAQ Market News